A Phase II/III Study to Evaluate the Immunogenicity, Safety and Lot-to-lot Consistency of LBVD, a Fully Liquid Hexavalent Diphtheria-tetanus-whole Cell Pertussis-hepatitis B-poliovirus-Haemophilus Influenzae Type b Conjugate (DTwP-HepB-IPV-Hib) Vaccine, in Healthy Infants as Primary Series
Clinical trial NCT06947499 · RECRUITING
Trial details
- NCT number
- NCT06947499
- Sponsor
- LG Chem
- Status
- RECRUITING
- Phase
- Phase 2, Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2025-05-30
- Primary completion
- 2026-11-01
- Enrollment
- 1186
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.